Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 2/20 | 0.44 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 5/20 | 0.39 |
| ▸ | BTK | Q06187 | 5/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21431006 | 0.84 | TGM2 (0.56) | TGM2GAAEGFRHPGDSMN1; SMN2 | |
| SCHEMBL1082208 | 0.83 | TGM2 (0.50) | TGM2HDAC1HDAC8HDAC6GAA | |
| SCHEMBL8151106 | 0.83 | TGM2 (0.49) | TGM2BRAFHDAC1HDAC3HDAC4 | |
| SCHEMBL1083277 | 0.81 | TDP1 (0.54) | TGM2SMN1; SMN2ALDH1A1MAPTMAPK1 | |
| SCHEMBL1082215 | 0.80 | TGM2 (0.57) | TGM2BRAFHDAC1HDAC3HDAC4 | |
| SCHEMBL3265331 | 0.78 | CA12 (0.56) | TGM2GAAHPGDSMN1; SMN2HTT | |
| SCHEMBL7122639 | 0.78 | GAA (0.56) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL1026723 | 0.77 | BRAF (0.56) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL3267660 | 0.76 | PTPRC (0.44) | TGM2GAAHPGDSMN1; SMN2HTT | |
| SCHEMBL4736951 | 0.76 | ABL1 (0.49) | TGM2GAAHPGDSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071197-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | BIOLIPOX AB (LV) | 2011-03-24 | — | — | US | disclosed |
| EP-2274280-A2 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | Biolipox AB (SE) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009127822-A2 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | BIOLIPOX AB (SE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071197-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | LTC4S, LTB4R2, LTB4R | TGM2 2255/4885BRAF 4179/4885HDAC1 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.